saruparib + darolutamide

**Saruparib + darolutamide** is a combination of two oral small molecule drugs being investigated primarily for prostate cancer, especially in settings of localized, high-risk, or metastatic castration-sensitive prostate cancer. - **Saruparib (AZD5305)** is a next-generation, highly selective PARP1 inhibitor that spares other members of the PARP family, aiming to drive synthetic lethality in tumor cells deficient in homologous recombination repair, such as those with BRCA mutations. - **Darolutamide** is a non-steroidal androgen receptor inhibitor (Nubeqa) that blocks the activity of the androgen receptor, a key driver in prostate cancer growth, including both hormone-sensitive and castration-resistant forms. The rationale for their combination lies in evidence that androgen receptor function and PARP-mediated DNA repair are interdependent and that dual inhibition may yield improved antitumor efficacy over either agent alone. Current clinical trials are focused on the biological effects and safety of this combination prior to radical prostatectomy and in metastatic settings, with endpoints including markers of DNA damage and cancer progression[1][3][5][6][7].

Brand names

Nubeqa

Other names

saruparib + NubeqaAZD5305 + Nubeqa